Cutera announced that its picosecond laser platform, enlighten, received US Food and Drug Administration 510(k) clearance for tattoo removal.

In August, 2014, enlighten received clearance for the treatment of benign pigmented lesions.

"The FDA clearance for tattoo removal for enlighten signifies a critical milestone not only for Cutera, but for the advancement of picosecond laser technology in the aesthetics market. Consistent with our innovative design philosophy, enlighten features industry-leading laser and optical design with advanced micro-electronics," said Kevin Connors, President and CEO of Cutera.

"The use of picosecond laser technology in aesthetic practices is evolving. With enlighten, practitioners are much closer to utilizing a single device for the vast majority of tattoo removal procedures," said Michael S. Kaminer, M.D., a board certified Dermatologist and Managing Partner of SkinCare Physicians in Chestnut Hill, Massachusetts, and one of the pre-eminent educators in cosmetic and aesthetic surgery.

Commercial shipments of enlighten are anticipated to commence in the fourth quarter, 2014.

Brisbane, California-based Cutera is a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide.
Since 1998, Cutera has been developing innovative, easy-to-use products that enable physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients.